LONDON - RTW Biotech Opportunities Ltd (LSE: RTW), a London Stock Exchange-listed investment company, has announced a new investment in Windward Bio's Series A funding round, which raised $200 ...

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD. Windward Bio .

Windward Bio AG was established with plans to both license a drug and establish wet labs to create an internal pipeline of drug candidates. SR One, Omega Funds, RTW Investments, Qiming Venture ...

Sea Island, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Young Women In Bio (YWIB) and Winward Academy are pleased to announce the launch of YWIB Teachers, a STEM-focused outreach program for teachers ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million biobucks for licensing rights to Kelun-Biotech and Harbour BioMed’s ...

Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio. 1 The clinical stage drug development company is developing treatments for immunological ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical ...

Harbour BioMed, a global biopharmaceutical company, announced that the company and Sichuan Kelun Biotech BioPharmaceutical have entered into a license agreement with Windward Bio AG (Windward Bio) for ...